ClinicalTrials.gg
RecruitingNCT07154264Updated Jun 22, 2026

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

A Phase 2 interventional study of DZD8586 and Venetoclax in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Dizal Pharmaceuticals. Recruiting at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Dizal Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China — 39 open to participants now, 60 under way, 19 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · China.

Planned enrollment
63rd of 105
66 · median 89
Started
2025
with 11 others
Phase 2
21 of 108
9 open now
Primary completion
2029-12
later than 47 of 59 live
Registered
97th of 108
by date
Lead sponsor
3 of 108
Dizal Pharmaceuticals

Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, this one is the 63rd largest by planned enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 47 of the 59 other live ones, and was the 97th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

39 of the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL.

This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.

03

Conditions studied

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female ≥ 18 years of age.
  2. performance status 0-2, and ≥ 6 months.
  3. Confirmed newly diagnosis or treatment naïve CLL/SLL with indication for treatment.
  4. Patients with SLL must have at least one .
  5. Adequate bone marrow reserve and organ functions.
  6. Willing to comply with restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Any of previous or current treatment prohibited by protocol.
  2. Any unresolved > grade 1 drug-related adverse events.
  3. Known or suspected Richter's transformation, or prolymphocytic leukemia.
  4. CNS involvement.
  5. Active infection.
  6. Any of severe cardiac or pulmonary abnormalities.
  7. Poorly controlled anemia or autoimmune thrombocytopenia.
  8. Poorly controlled gastrointestinal disorder, inadequate absorption of medication or other systemic diseases.
  9. Prior within the past 3 years.
  10. Known allergy to study drugs, any of the ingredients of the study drugs, or xanthine oxidase inhibitors or rasburicase.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Combination of DZD8586 and Venetoclax

    DZD8586 will be taken orally once daily on days 1-28 of each cycle. Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.

    Drug: DZD8586 · Drug: Venetoclax

Interventions

  • DZD8586 will be taken orally once daily on days 1-28 of each cycle.

    Also known as: Birelentinib

  • Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.

06

What researchers measure

Primary outcomes

  1. Part A: Incidence of Adverse Events

    Time frame: 30 days after the last dose

  2. Part B: 2-year progression free survival (PFS) rate assessed by investigator

    Time frame: Approximately 5 years

Secondary outcomes

  1. Part A: PFS assessed by investigator

    Time frame: Approximately 5 years

  2. Part A: Objective response rate (ORR) assessed by investigator

    Time frame: Approximately 5 years

  3. Part B: ORR assessed by investigator

    Time frame: Approximately 5 years

  4. Part B: Incidence of Adverse Events

    Time frame: 30 days after the last dose

07

Study locations

14 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2029, 51 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's planned 51 months is close to that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Sep 4, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Dec 2029
CompletionEst.
Jan 2030
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154264
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Sep 22, 2025
Primary completion
Dec 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Jun 22, 2026

Study contacts

Ling Zhou
Contact
ling.zhou@dizalpharma.com
0086-21-61095755
Niu
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Birelentinib

Start the discussion